CN111714537B - Film agent capable of relieving chest drop and atrophy and preparation method thereof - Google Patents

Film agent capable of relieving chest drop and atrophy and preparation method thereof Download PDF

Info

Publication number
CN111714537B
CN111714537B CN202010787864.8A CN202010787864A CN111714537B CN 111714537 B CN111714537 B CN 111714537B CN 202010787864 A CN202010787864 A CN 202010787864A CN 111714537 B CN111714537 B CN 111714537B
Authority
CN
China
Prior art keywords
parts
solution
purified water
polyvinyl alcohol
atrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010787864.8A
Other languages
Chinese (zh)
Other versions
CN111714537A (en
Inventor
李剑平
马关保
孙洪书
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heilongjiang Pharmaceutical Co ltd
Original Assignee
Heilongjiang Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heilongjiang Pharmaceutical Co ltd filed Critical Heilongjiang Pharmaceutical Co ltd
Priority to CN202010787864.8A priority Critical patent/CN111714537B/en
Publication of CN111714537A publication Critical patent/CN111714537A/en
Application granted granted Critical
Publication of CN111714537B publication Critical patent/CN111714537B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A film agent capable of relieving chest drop and atrophy and a preparation method thereof relate to the technical field of biology. The invention aims to solve the problems that in the existing countermeasures for mastoptosis, the maintenance products of beauty parlors contain hormone components, have great side effects on human bodies, have the defects of great pain, high risk and the like in clinical operation treatment, have slow diet improvement method effect, are difficult to adhere to most people, have poor transdermal effect after the existing nursing milk is used, and cannot promote metabolism. The method comprises the following steps: dispersing carbomer dry powder in purified water to obtain solution A; adding polyvinyl alcohol into purified water, and performing ultrasonic treatment to obtain a solution B; adding polyvinylpyrrolidone and sodium carboxymethylcellulose into purified water, and adding into the solution B to obtain a solution C; adding the solution A into the solution C, stirring, adding fenugreek essential oil, glycerol and azone, and mixing to obtain pellicle. The invention can obtain a film agent capable of relieving breast ptosis and atrophy and a preparation method thereof.

Description

Film agent capable of relieving chest drop and atrophy and preparation method thereof
Technical Field
The invention relates to the technical field of biology, and in particular relates to a film agent capable of relieving chest sagging and atrophy and a preparation method thereof.
Background
Breasts are an important secondary trait of women, and in addition to breast-feeding effects, have an important role in demonstrating the beauty of women. Mastoptosis is an abnormality of the shape and position of the breast, which destroys the female body and the natural beauty of the breast. According to medical studies, the main component of a female breast is the fatty glands, including tissues such as blood vessels, lymph glands and nerve glands. After lactation in women, the mammary glands begin to degenerate and the breast volume decreases. After the adult period, fat in the mammary gland is increased, gland structures such as lobules and ductus lactici are reduced, the fat is deposited, and the skin on the surface of the breast is loosened, so that the breast gradually sags, and the phenomenon becomes more obvious along with the increase of the age.
The existing countermeasures for mastoptosis are mainly as follows: nursing in beauty parlor, clinical operation and diet improvement. The maintenance cost of a beauty shop is high, and part of the used products contain hormone components and have great side effects on human bodies; the clinical operation treatment has the defects of great pain, high risk and the like; diet improvement is safe, but the effect is slow, and most people are hard to insist on. The prior nursing milk has poor transdermal effect after use and can not promote metabolism.
Disclosure of Invention
The invention aims to solve the problems that in the existing countermeasures for mastoptosis, products for nursing department of beauty parlors contain hormone components, have great side effects on human bodies, have great pain and high risk in clinical operation treatment, have slow diet improvement method effect, are difficult to persist by most people, have poor transdermal effect after the existing nursing milk is used, and cannot promote metabolism, and provides a film agent capable of relieving mastoptosis and atrophy and a preparation method thereof.
A film agent capable of relieving chest sagging and atrophy is composed of, by weight, 9-11 parts of fenugreek essential oil, 12-13 parts of polyvinyl alcohol, 6-7 parts of polyvinylpyrrolidone, 4-5 parts of sodium carboxymethylcellulose, 7-9 parts of carbomer dry powder, 2-4 parts of azone, 4-6 parts of glycerol and purified water.
A preparation method of a film agent capable of relieving chest sagging and atrophy comprises the following steps:
firstly, weighing raw materials: weighing 9-11 parts of fenugreek essential oil, 12-13 parts of polyvinyl alcohol, 6-7 parts of polyvinylpyrrolidone, 4-5 parts of sodium carboxymethylcellulose, 7-9 parts of carbomer dry powder, 2-4 parts of azone, 4-6 parts of glycerol and purified water in parts by weight;
dispersing carbomer dry powder in 10-30 parts of purified water, and standing for 24-48 hours to obtain a solution A; adding polyvinyl alcohol into 10-30 parts of purified water, and performing ultrasonic treatment for 60-80 min to obtain a solution B; adding polyvinylpyrrolidone and sodium carboxymethylcellulose into 10-30 parts of purified water, stirring for 30-60 min, adding into the solution B, and uniformly mixing to obtain a solution C; and adding the solution A into the solution C, stirring for 20-40 min, sequentially adding the fenugreek essential oil, the glycerol and the azone, and uniformly mixing to obtain the film agent.
The invention has the beneficial effects that:
the invention relates to a film agent capable of relieving breast drop and atrophy and a preparation method thereof, wherein a transdermal absorbent azone, a moisturizing component glycerol, a film forming agent polyvinyl alcohol (PVA-1788), polyvinylpyrrolidone (PVP), sodium carboxymethylcellulose, a breast enhancement plant factor fenugreek essential oil and other components are added, and the film agent has stable transdermal speed and the effect of promoting metabolism of a user due to the breast enhancement factor characteristic and the transdermal absorption characteristic in the components, and meanwhile, the synergistic effect of film forming and stretching is added, so that the breast drop and atrophy are prevented, and an ideal breast enhancement effect is achieved; meanwhile, the film agent does not contain hormone components, has no side effect on human bodies, does not need operation treatment, and has no pain and no risk.
The invention can obtain a film agent capable of relieving breast ptosis and atrophy and a preparation method thereof.
Drawings
FIG. 1 is a graph showing the effect of different concentrations of film on the proliferation of L6 cells in example two, wherein a represents a control group, b represents a 2% film, c represents a 5% film, and d represents a 10% film;
FIG. 2 is a graph showing the effect of different groups of media on collagen type I secretion by fibroblasts in example two.
Detailed Description
The first embodiment is as follows: the film agent capable of relieving chest sagging and atrophy in the embodiment comprises, by weight, 9-11 parts of fenugreek essential oil, 12-13 parts of polyvinyl alcohol, 6-7 parts of polyvinylpyrrolidone, 4-5 parts of sodium carboxymethylcellulose, 7-9 parts of carbomer dry powder, 2-4 parts of azone, 4-6 parts of glycerol and purified water.
The fenugreek essential oil is used as a breast enhancement plant factor and has the breast enhancement effect; polyvinyl alcohol, polyvinylpyrrolidone and sodium carboxymethylcellulose are all film forming agents; carbomer dry powder is an emulsifier; the azone is taken as a transdermal absorbent, and can effectively promote transdermal absorption; glycerol has good moisture keeping effect.
The second embodiment is as follows: the present embodiment differs from the present embodiment in that: the film agent consists of 10 parts of fenugreek essential oil, 12.5 parts of polyvinyl alcohol, 6.5 parts of polyvinylpyrrolidone, 4.5 parts of sodium carboxymethylcellulose, 8 parts of carbomer dry powder, 3 parts of azone, 5 parts of glycerol and purified water in parts by weight.
Other steps are the same as those in the first embodiment.
The third concrete implementation mode: the first or second differences from the present embodiment are as follows: the polyvinyl alcohol is of a type of polyvinyl alcohol 1788.
The other steps are the same as those in the first or second embodiment.
The fourth concrete implementation mode: the preparation method of the film agent capable of relieving chest sagging and atrophy in the embodiment comprises the following steps:
firstly, weighing raw materials: weighing 9-11 parts of fenugreek essential oil, 12-13 parts of polyvinyl alcohol, 6-7 parts of polyvinylpyrrolidone, 4-5 parts of sodium carboxymethylcellulose, 7-9 parts of carbomer dry powder, 2-4 parts of azone, 4-6 parts of glycerol and purified water in parts by weight;
dispersing carbomer dry powder in 10-30 parts of purified water, and standing for 24-48 hours to obtain a solution A; adding polyvinyl alcohol into 10-30 parts of purified water, and performing ultrasonic treatment for 60-80 min to obtain a solution B; adding polyvinylpyrrolidone and sodium carboxymethylcellulose into 10-30 parts of purified water, stirring for 30-60 min, adding into the solution B, and uniformly mixing to obtain a solution C; and adding the solution A into the solution C, stirring for 20-40 min, sequentially adding the fenugreek essential oil, the glycerol and the azone, and uniformly mixing to obtain the film agent.
The beneficial effects of the embodiment are as follows:
the membrane agent capable of relieving chest drop and atrophy and the preparation method thereof are characterized in that components such as a transdermal absorbent azone, a moisturizing component glycerol, a membrane forming agent polyvinyl alcohol (PVA-1788), polyvinylpyrrolidone (PVP), sodium carboxymethylcellulose and a breast enhancement plant factor fenugreek essential oil are added, and due to the characteristics of the breast enhancement factor and the transdermal absorption characteristic of the components, the membrane agent has stable transdermal speed and the effect of promoting metabolism of a user, and meanwhile, the synergistic effect of membrane forming and stretching is added, so that chest drop and atrophy are prevented, and an ideal breast enhancement effect is achieved; meanwhile, the film agent of the embodiment does not contain hormone components, has no side effect on human bodies, does not need operation treatment, and has no pain and no risk.
The fifth concrete implementation mode: the difference between this embodiment and one of the first to fourth embodiments is: in the step one, 10 parts of fenugreek essential oil, 12.5 parts of polyvinyl alcohol, 6.5 parts of polyvinylpyrrolidone, 4.5 parts of sodium carboxymethylcellulose, 8 parts of carbomer dry powder, 3 parts of azone, 5 parts of glycerol and purified water are weighed according to parts by weight.
The other steps are the same as those in the first to fourth embodiments.
The sixth specific implementation mode: the difference between this embodiment and one of the first to fifth embodiments is as follows: the polyvinyl alcohol in the step one is polyvinyl alcohol 1788.
The other steps are the same as those in the first to fifth embodiments.
The seventh embodiment: the difference between this embodiment and one of the first to sixth embodiments is: and dispersing the carbomer dry powder in 20 parts of purified water, and standing for 24 hours to obtain a solution A.
The other steps are the same as those in the first to sixth embodiments.
The specific implementation mode is eight: the difference between this embodiment and one of the first to seventh embodiments is: and step two, adding polyvinyl alcohol into 20 parts of purified water, and performing ultrasonic treatment for 60min to obtain a solution B.
The other steps are the same as those in the first to seventh embodiments.
The specific implementation method nine: the difference between this embodiment and the first to eighth embodiments is: and step two, adding the polyvinylpyrrolidone and the sodium carboxymethylcellulose into 15 parts of purified water, stirring for 30min, adding into the solution B, and uniformly mixing to obtain a solution C.
The other steps are the same as those in the first to eighth embodiments.
The detailed implementation mode is ten: the difference between this embodiment and one of the first to ninth embodiments is as follows: and step two, adding the solution A into the solution C, stirring for 20min, sequentially adding the fenugreek essential oil, the glycerol and the azone, and uniformly mixing to obtain the film agent.
The other steps are the same as those in the first to ninth embodiments.
The following examples were used to demonstrate the beneficial effects of the present invention:
the first embodiment is as follows: a film agent capable of relieving chest drop and atrophy comprises, by weight, 10 parts of fenugreek essential oil, 12.5 parts of polyvinyl alcohol, 6.5 parts of polyvinylpyrrolidone, 4.5 parts of sodium carboxymethylcellulose, 8 parts of carbomer dry powder, 3 parts of azone, 5 parts of glycerol and purified water.
Example two: a preparation method of a film agent capable of relieving chest sagging and atrophy comprises the following steps:
firstly, weighing raw materials: weighing 10 parts of fenugreek essential oil, 12.5 parts of polyvinyl alcohol, 6.5 parts of polyvinylpyrrolidone, 4.5 parts of sodium carboxymethylcellulose, 8 parts of carbomer dry powder, 3 parts of azone, 5 parts of glycerol and purified water in parts by weight;
dispersing carbomer dry powder in 20 parts of purified water, and standing for 24 hours to obtain a solution A; adding polyvinyl alcohol into 20 parts of purified water, and performing ultrasonic treatment for 60min to obtain a solution B; adding polyvinylpyrrolidone and sodium carboxymethylcellulose into 15 parts of purified water, stirring for 30min, adding into the solution B, and mixing uniformly to obtain a solution C; adding the solution A into the solution C, stirring for 20min, sequentially adding fenugreek essential oil, glycerol and azone, mixing uniformly to obtain a film agent, and forming a film agent to obtain the film agent.
Thirdly, effect verification:
1. transdermal absorption effect:
the experimental method comprises the following steps:
the artificial biomembrane is used for simulating human epidermal skin, is cut into 4cm multiplied by 4cm, and is soaked in physiological saline for 40min to be used as a transdermal barrier. 2 percent of water-soluble vitamin E-physiological saline and the film agent of the embodiment are used as transdermal release liquid, 30 percent of ethanol-physiological saline is used as transdermal absorption liquid, and a transdermal absorption experiment is carried out under the conditions of constant temperature of 37 ℃ and constant speed of 3800 r/min. Transferring 2mL of the permeate with a syringe at 0.5h, 1h, 2h, 4h, 8h, 12h and 24h, respectively, and supplementing 2mL of 30% ethanol-physiological saline. The water-soluble vitamin E and the effective component concentration of the film agent of the embodiment are respectively measured by the permeate of each sampling point to obtain the stable transdermal speed J (mg cm)2·h-1)。
② experimental results:
table 1 shows the transdermal rates of the different solutions;
TABLE 1
2% water-soluble vitamin E-physiological saline Film agent of this example
J value 0.726±0.012 1.043±0.015
As can be seen from Table 1, the transdermal rate of the film of the present embodiment is significantly higher than that of 2% water-soluble vitamin E-physiological saline (P < 0.05), and the stable transdermal rate of the film of the present embodiment is more advantageous.
2. The metabolism effect is increased:
the experimental method comprises the following steps:
rat L6 myocytes were cultured in medium containing 10% fetal calf serum (90% DMEM + 10% fetal calf serum + 1% double antibody) and then placed at 37 ℃ in 5% CO2Culturing in an incubator. L6 cells were seeded in a 96-well plate, and the 96-well plate was cultured in an incubator (37 ℃ C., 5% CO)2) After 12h, each group was added with the final concentration of 2%, 5%, 10% of the film of this example, and each treatment group was repeated 3 times and cultured for 24h, 48h, 72h, respectively. 10uLCCK-8 was then added to each well, incubated in an incubator for 1-4h, and the absorbance at 450nm was measured using a microplate reader.
② experimental results:
FIG. 1 is a graph showing the effect of different concentrations of film agents on L6 cell proliferation in example two;
as shown in FIG. 1, when the film agents of the present example were added at different concentrations and cultured for 24h, the proliferation rate of L6 cells did not differ significantly between the concentrations. After further incubation for 48h and 72h, the effect of the film agent of this example gradually appeared. At 48h and 72h, the cell proliferation rate was significantly higher than that of the control group (P < 0.05) when 2% was added, and the cell proliferation rate was significantly higher than that of the control group (P < 0.01) when 5% and 10% were added.
3. The effect of preventing drooping:
the experimental method comprises the following steps:
according to medical studies, the classification of the degree of mastoptosis is shown below:
slight sagging: the inframammary pole exceeds the inframammary fold by 1-2 cm;
moderate sag: the inframammary pole exceeds the inframammary fold by 2-3 cm;
severe sagging: the inframammary pole exceeds the inframammary fold by 4-10 cm;
extra-heavy droop: the inframammary pole exceeds the inframammary fold by more than 10 cm.
For a pharmacodynamic review:
80 female volunteers of 28-52 years old with heavily pendulous breasts were selected, and had no mammary diseases and adverse hobbies. After the chest is cleaned, the second film agent of the example is evenly smeared on the chest, and the second film agent of the example is picked off after 20 minutes and cleaned by clean water, and is used for 2 times per week. The length of the inframammary fold and the upper chest circumference of each volunteer were measured before the start of the test, and the test was divided into 4 groups of 20 persons, each group being administered with the product for 4, 8, 12 and 16 consecutive weeks, respectively. After the test is finished, the length of the inframammary fold exceeding the inframammary fold and the upper bust of each volunteer are measured.
② experimental results:
table 2 shows the change in the degree of mastoptosis after different times using the example two films;
TABLE 2
Figure BDA0002625902240000061
As can be seen from table 2, after 16 weeks of using the example two film agent, all volunteers with heavily sagging breasts became slightly sagging and the chest circumference increased by more than 2 cm.
4. The atrophy prevention effect is as follows:
the experimental method comprises the following steps:
the experiment was divided into 4 groups, and the final concentrations of the film agents of this example were made 0%, 1%, 2% and 5% in the medium, respectively. Taking 4-6 generation fibroblast of logarithmic growth phase, digesting with 0.25% pancreatin to obtain single cell suspension, and mixing at a ratio of 1 × 105Cell count/mL, inoculated into a petri dish, added with 4 groups of medium, placed at 37 ℃ with 5% CO2When 70-80% of cells are fused, digesting the cells by using 0.25% trypsin solution, collecting the digested cells, centrifuging for 5min at 1000r/min, removing supernatant, and adding a DMEM (DMEM) culture medium (containing 10% calf serum) to prepare single cell suspension. Detecting the level of I type collagen secreted by fibroblasts by an ELISA method, finding out the content of the I type collagen on a standard curve according to the OD value of a sample, and calculating the concentration value of the I type collagen according to the initial dilution ratio.
② experimental results:
FIG. 2 is a graph showing the effect of different groups of media on collagen type I secretion by fibroblasts;
as shown in FIG. 2, the membrane agents of this example were added to the medium to give final concentrations of 1%, 2% and 5%, respectively, and the content of type I collagen secreted from fibroblasts was higher than that of cells cultured in the medium without the membrane agents of this example.

Claims (2)

1. The film agent capable of relieving breast sagging and atrophy is characterized by comprising, by weight, 10 parts of fenugreek essential oil, 12.5 parts of polyvinyl alcohol, 6.5 parts of polyvinylpyrrolidone, 4.5 parts of sodium carboxymethylcellulose, 8 parts of carbomer dry powder, 3 parts of azone, 5 parts of glycerol and purified water, wherein the polyvinyl alcohol is polyvinyl alcohol 1788.
2. The method of preparing a film for relieving chest sagging and atrophy as claimed in claim 1, wherein the preparing method is completed by the following steps:
firstly, weighing raw materials: weighing 10 parts of fenugreek essential oil, 12.5 parts of polyvinyl alcohol, 6.5 parts of polyvinylpyrrolidone, 4.5 parts of sodium carboxymethylcellulose, 8 parts of carbomer dry powder, 3 parts of azone, 5 parts of glycerol and purified water in parts by weight; the type of the polyvinyl alcohol is polyvinyl alcohol 1788;
dispersing carbomer dry powder in 20 parts of purified water, and standing for 24 hours to obtain a solution A; adding polyvinyl alcohol into 20 parts of purified water, and performing ultrasonic treatment for 60min to obtain a solution B; adding polyvinylpyrrolidone and sodium carboxymethylcellulose into 15 parts of purified water, stirring for 30min, adding into the solution B, and mixing uniformly to obtain a solution C; and adding the solution A into the solution C, stirring for 20min, sequentially adding fenugreek essential oil, glycerol and azone, and uniformly mixing to obtain the film agent.
CN202010787864.8A 2020-08-10 2020-08-10 Film agent capable of relieving chest drop and atrophy and preparation method thereof Active CN111714537B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010787864.8A CN111714537B (en) 2020-08-10 2020-08-10 Film agent capable of relieving chest drop and atrophy and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010787864.8A CN111714537B (en) 2020-08-10 2020-08-10 Film agent capable of relieving chest drop and atrophy and preparation method thereof

Publications (2)

Publication Number Publication Date
CN111714537A CN111714537A (en) 2020-09-29
CN111714537B true CN111714537B (en) 2022-02-18

Family

ID=72574268

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010787864.8A Active CN111714537B (en) 2020-08-10 2020-08-10 Film agent capable of relieving chest drop and atrophy and preparation method thereof

Country Status (1)

Country Link
CN (1) CN111714537B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102258455A (en) * 2010-05-28 2011-11-30 上海市计划生育科学研究所 Film coating agent containing steroid hormone and its preparation method
CN108578307A (en) * 2018-08-03 2018-09-28 吴碧云 It is a kind of to improve care cream of breast hanging down and preparation method thereof
CN110511169A (en) * 2019-07-31 2019-11-29 浙江九如堂生物科技有限公司 The method for preparing Determination of Astaxanthin in Haematococcus Pluvialis based on Transdermal absorption

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106109473A (en) * 2016-08-31 2016-11-16 孙华燕 A kind of compound vitamin A acid liniment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102258455A (en) * 2010-05-28 2011-11-30 上海市计划生育科学研究所 Film coating agent containing steroid hormone and its preparation method
CN108578307A (en) * 2018-08-03 2018-09-28 吴碧云 It is a kind of to improve care cream of breast hanging down and preparation method thereof
CN110511169A (en) * 2019-07-31 2019-11-29 浙江九如堂生物科技有限公司 The method for preparing Determination of Astaxanthin in Haematococcus Pluvialis based on Transdermal absorption

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
复方乳没利多卡因缓释贴膜的制剂工艺研究;师有栋等;《卫生职业教育》;20141231;第32卷(第22期);第91-92页，第2.1.2节 *
葫芦巴精油;无;《https://www.ilife.cn/zhuanti/huluba/294999.html》;20181205;第1-2页，第1段 *

Also Published As

Publication number Publication date
CN111714537A (en) 2020-09-29

Similar Documents

Publication Publication Date Title
CN108524601B (en) Vaginal gel containing pleiotropic factors and preparation method thereof
CN113073070B (en) Bifidobacterium longum, application and product thereof
CN111803408A (en) Dischizosaccharomyces cerevisiae fermentation product filtrate and application thereof in skin care products
EP3711779A1 (en) Application of pharmaceutical composition in regulation of fibroblast growth
CN113057930A (en) Mite-removing face cream containing rosemary and preparation method thereof
CN111714537B (en) Film agent capable of relieving chest drop and atrophy and preparation method thereof
CN113318166A (en) Plant composition and preparation method and application thereof
CN107236032A (en) A kind of method that multiple cytokine is extracted from umbilical cord tissue
CN111759896A (en) Pharmaceutical application of total triterpene of pawpaw
CN116898765A (en) Compound cosmetic raw material composition with synergistic anti-inflammatory effect and application thereof
CN102935060A (en) Pasties for breasts of women
CN109182261A (en) A method of culture amnion mesenchymal stem cell
CN102793832B (en) Novel micro-ecological modulator and preparation method thereof
CN105534879B (en) Suppository and preparation method thereof
EP3247461B1 (en) Composition for lymph drainage
CN110974935A (en) Antibacterial nursing gel containing fullerene C60 component and preparation method thereof
CN108310015A (en) Umbilical cord mesenchymal stem cells Cocktail treatment hyperglycemia and diabetic nephropathy
CN115192696B (en) Active antibacterial gynecological lotion and preparation method thereof
CN116942750B (en) Medicine for treating colpitis
CN108210518A (en) Umbilical cord mesenchymal stem cells Cocktail treatment hyperglycemia and diabetic nephropathy
CN116672352B (en) Pharmaceutical composition for eczema and application thereof
CN113069376A (en) Skin micro-ecological regeneration and restoration essence and preparation method thereof
CN116549345A (en) Oil-control and soothing plant fermentation product and preparation method and application thereof
CN117756912A (en) Composite cytokine and application thereof in preparation of striae gravidarum repair emulsion
CN115282111A (en) Body lotion with effects of relieving swelling, relieving itching and moisturizing and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant